N-(4-aminophenyl)-N,2-dimethylquinazolin-4-amine | 827031-35-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(4-aminophenyl)-N,2-dimethylquinazolin-4-amine
• 英文别名: (4-amino-phenyl)-(2-methyl-quinazolin-4-yl)-methyl-amine；(2-methyl-quinazolin-4-yl)-(4-amino-phenyl)-methylamine；(4-amino-phenyl)-(2-methyl-quinazolin-4-yl)-methylamine；N-methyl-N-(2-methylquinazolin-4-yl)benzene-1,4-diamine；4-N-methyl-4-N-(2-methylquinazolin-4-yl)benzene-1,4-diamine
• CAS: 827031-35-6
• 化学式: C₁₆H₁₆N₄
• 分子量: 264.33
• InChiKey: VJPRMSSYQNPZGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  55
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(4-aminophenyl)-N,2-dimethylquinazolin-4-amine 在 溴 、 溶剂黄146 作用下， 生成 (2-methyl-quinazolin-4-yl)-(4-amino-2,6-dibromo-phenyl)-methyl-amine
  参考文献：
  名称：

  Discovery of N-(4-Methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a Potent Apoptosis Inducer and Efficacious Anticancer Agent with High Blood Brain Barrier Penetration

  摘要：

  As a continuation of our structure-activity relationship (SAR) studies on 4-anilinoquinazolines as potent apoptosis inducers and to identify anticancer development candidates, we explored the replacement of the 2-Cl group in our lead compound 2-chloro-N-(4-methoxyphenyl)-N-methylquinazolin-4-amine (6b, EP 128265, MPI-0441138) by other functional groups. This SAR study and lead optimization resulted in the identification of N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine (6h EP128495, MPC-6827) as an anticancer clinical candidate. Compound 6h was found to be a potent apoptosis inducer with EC50 of 2 nM in our cell-based apoptosis induction assay. It also has excellent blood brain barrier penetration, and is highly efficacious in human MX-1 breast and other mouse xenograft cancer models.

  DOI：

  10.1021/jm801315b
• 作为产物：
  描述：

  N-甲基对硝基苯胺 在 5%-palladium/activated carbon 、 氢气 作用下， 以 甲醇 、 异丙醇 为溶剂， 生成 N-(4-aminophenyl)-N,2-dimethylquinazolin-4-amine
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of quinazoline derivatives as dual HDAC1 and HDAC6 inhibitors for the treatment of cancer

  摘要：

  AbstractFifty‐eight quinazoline‐based compounds were designed and synthesized based on the structural optimizations from the lead compound 23bb in an attempt to search for more potent dual HDAC1 and HDAC6 inhibitors. Among them, 32c (HDAC1, IC50 = 31.10 ± 0.37 nM; HDAC6, IC50 = 16.15 ± 0.62 nM) and 32d (HDAC1, IC50 = 37.00 ± 0.24 nM; HDAC6, IC50 = 35.00 ± 0.71 nM) were not only identified as potent dual‐acting HDAC1 and HDAC6 inhibitors with over 10‐fold selectivity to the other HDACs, but also displayed activities in tubulin acetylation and histone H3 acetylation induction. Importantly, both of them displayed strong antiproliferative activities against various tumor cell lines in vitro with IC50 values less than 40 nM, especially for hematologic tumors cells (U266 and RPMI8226, IC50 < 1 nM), which were even better than 23bb and SAHA. Furthermore, 32c showed a significant tumor growth inhibition (antitumor rate = 63.98%, p < 0.05) in the resistant MCF‐7/ADR xenograft model without any obvious body weight changes and abnormal behaviors. Our findings validate that 32c is a potent dual inhibitor of HDAC1/6 that can be an efficacious treatment for breast cancer with Adriamycin resistance.

  DOI：

  10.1111/cbdd.13405

文献信息

• COMPOUNDS AND THERAPEUTICAL USE THEREOF
  申请人：Cai Xiong Sui

  公开号：US20070244113A1

  公开（公告）日：2007-10-18

  Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明揭示了4-芳氨基喹唑啉及其类似物，可有效激活半胱氨酸蛋白酶并诱导细胞凋亡。本发明的化合物在治疗各种临床情况中具有用途，其中异常细胞的不受控制的生长和扩散。
• Compounds and therapeutical use thereof
  申请人：Cai Xiong Sui

  公开号：US20050137213A1

  公开（公告）日：2005-06-23

  Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明揭示了4-芳基氨基喹唑啉及其类似物，它们有效地激活半胱氨酸蛋白酶并诱导细胞凋亡。本发明的化合物在治疗各种临床病症中具有用途，其中发生异常细胞的不受控制的生长和扩散。
• METHOD OF TREATING BRAIN CANCER
  申请人：Cai Sui Xiong

  公开号：US20080051398A1

  公开（公告）日：2008-02-28

  Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to the use of these compounds in treating brain cancer.

  本发明涉及4-芳基氨基喹唑啉及其类似物，其有效激活caspases并诱导细胞凋亡。本发明的化合物可用于治疗各种临床病症，其中发生异常细胞的不受控制的生长和扩散，特别是用于治疗脑癌。
• 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
  申请人：Myriad Pharmaceuticals, Inc.

  公开号：US07618975B2

  公开（公告）日：2009-11-17

  Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明揭示了4-芳基氨基喹唑啉及其类似物，其作为caspase激活剂和诱导凋亡剂具有有效性。本发明的化合物在治疗各种临床病症中有用，其中发生异常细胞的不受控制的生长和扩散。
• 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
  申请人：Myrexis, Inc.

  公开号：US07989462B2

  公开（公告）日：2011-08-02

  Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明涉及4-芳基氨基喹唑啉及其类似物，可作为caspase激活剂和凋亡诱导剂。该发明的化合物可用于治疗多种临床情况，其中发生异常细胞的不受控制的生长和扩散。